FDA GRANTS U.S. MARKETING APPROVAL OF FANAPT(TM) (ILOPERIDONE)
ROCKVILLE, Md., Aug. 10 /PRNewswire-FirstCall/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a biopharmaceutical
company focused on the development and commercialization of
clinical-stage products for central nervous system disorders, today
announced financial and operational results for the second quarter
ended June 30, 2009. Vanda reported a net loss of $12.4 million for
the second quarter of 2009, compared to $6.5 million for the first
quarter of 2009 and $13.5 million for the second quarter of 2008.
Total expenses for the second quarter of 2009 were $12.4 million,
compared to $6.6 million for the first quarter of 2009 and $13.9
million for the second quarter of 2008. Research and development
(R&D) expenses for the second quarter of 2009 were $7.2
million, compared to $2.3 million for the first quarter of 2009 and
$5.5 million for the second quarter of 2008. The increase in
R&D expenses in the second quarter of 2009 relative to the
first quarter of 2009 and second quarter of 2008 is primarily due
to the regulatory consulting fees paid and/or accrued as a result
of the approval of Fanapt(TM) (iloperidone) by the U.S. Food and
Drug Administration (FDA). In addition, the Company recorded a
$12.0 million milestone payment due to Novartis as an intangible
asset. Of the $12.0 million milestone payment, $7.0 million was
paid in May 2009 and the remaining $5.0 million is due in November
2009; however, Novartis has the right to accelerate the due date in
its sole discretion. As of June 30, 2009, Vanda's cash, cash
equivalents, and marketable securities totaled approximately $29.0
million. As of June 30, 2009, a total of approximately 27.1 million
shares of Vanda common stock were outstanding. Net loss per common
share for the second quarter of 2009 was $0.46, compared to $0.24
for the first quarter of 2009 and $0.51 for the second quarter of
2008. OPERATIONAL HIGHLIGHTS On May 6, 2009, the FDA granted U.S.
marketing approval of Fanapt(TM) for the acute treatment of
schizophrenia in adults. Vanda expects to make Fanapt(TM) available
in U.S. pharmacies later this year. Holders of a New Drug
Application (NDA) have 60 days after approval to file for patent
term restoration under the Hatch-Waxman Act. Vanda submitted its
application for patent term restoration with respect to Fanapt(TM)
on June 9, 2009. Vanda also continues to pursue its clinical
development plan for tasimelteon for the treatment of circadian
rhythm sleep disorders. On June 26, 2009, Vanda met with the FDA to
discuss the clinical development plan in an End of Phase II
Meeting. Vanda will continue to work with the FDA to characterize
the path to an NDA for tasimelteon. FINANCIAL DETAILS -- Operating
Expenses. Second quarter 2009 R&D expenses of $7.2 million
consisted primarily of $5.4 million of consulting fees, as well as
$0.6 million of salaries and benefits, $0.6 million of non-cash
stock based compensation costs for R&D personnel, and $0.3
million of pre-clinical work. This compares to $2.3 million for the
first quarter of 2009 and $5.5 million for the second quarter of
2008. The increase in R&D expenses in the second quarter of
2009 relative to the first quarter of 2009 and second quarter of
2008 is primarily due to the $5.0 million in regulatory consulting
fees paid and/or accrued as a result of the approval of Fanapt(TM)
by the FDA. -- General and administrative (G&A) expenses of
$5.0 million for the second quarter of 2009 consisted primarily of
$0.5 million of salaries and benefits and $2.2 million of non-cash
stock based compensation costs for G&A personnel, as well as
$0.6 million of legal fees, $0.7 million of commercial costs and
$0.2 million of insurance costs. This compares to $4.2 million for
the first quarter of 2009 and $8.5 million for the second quarter
of 2008. The increase in G&A expenses in the second quarter of
2009 relative to the first quarter of 2009 is primarily due to an
increase in professional fees and commercial costs related to
Vanda's participation at the American Psychiatric Association's
Annual Meeting in May. The decrease in G&A expenses in the
second quarter of 2009 relative to the second quarter of 2008 is
primarily due to lower stock-based compensation and commercial
expenses. -- Employee stock-based compensation expense recorded in
the second quarter of 2009 totaled $2.8 million. Of these non-cash
charges, $0.6 million was recorded as R&D expense and $2.2
million was recorded as G&A expense. For the first quarter of
2009 and the second quarter of 2008, total stock-based compensation
expense was $2.3 million and $4.0 million, respectively. The
increase in stock-based compensation expense in the second quarter
of 2009 relative to the first quarter of 2009 is the result of the
issuance of additional non-qualified stock options in the second
quarter, as well as the expense related to the vesting of
restricted stock units upon the approval of Fanapt(TM) by the FDA.
The decrease in stock-based compensation expense in the second
quarter of 2009 relative to the second quarter of 2008 is primarily
due to a lower stock-based compensation expense resulting from the
workforce reduction in the fourth quarter of 2008. -- Cash and
marketable securities decreased by $13.6 million during the second
quarter of 2009. Changes included $12.4 million of net losses,
increases of $1.3 million in inventory and $7.0 million in
intangible assets offset by increases in accrued expenses and
accounts payable of $2.9 million, $3.4 million in non-cash
depreciation, amortization, and stock-based compensation expense,
$0.9 million in proceeds from the exercise of stock options and
$0.1 million of other working capital outflows. -- Vanda's cash,
cash equivalents and marketable securities as of June 30, 2009
totaled approximately $29.0 million, compared to approximately
$46.5 million as of December 31, 2008. -- Net loss for the second
quarter of 2009 was $12.4 million, compared to a net loss of $6.5
million for the first quarter of 2009 and a net loss of $13.5
million for the second quarter of 2008. -- Net loss per common
share for the second quarter of 2009 was $0.46, compared to $0.24
for the first quarter of 2009 and $0.51 for the second quarter of
2008. FINANCIAL GUIDANCE Based on its current operating plans,
Vanda believes that its existing cash, cash equivalents and
marketable securities, will be sufficient to meet its anticipated
operating needs through 2009. However, given the recent approval by
the FDA of the NDA for Fanapt(TM), Vanda is currently evaluating
alternative commercial strategies for the product. These strategies
include, in addition to Vanda launching Fanapt(TM) on its own,
entering into one or more partnerships, other collaboration
agreements or strategic transactions that may provide capital to
support Vanda's operations. CONFERENCE CALL Vanda has scheduled a
conference call for today, Monday, August 10, 2009, at 10:00 AM ET.
During the call, Mihael H. Polymeropoulos, M.D., President and CEO,
and Stephanie Irish, Acting CFO, will discuss quarterly results and
other corporate activities. Investors can call 1-800-599-9829
(domestic) and 1-617-847-8703 (international) prior to the 10:00 AM
start time and ask for the Vanda Pharmaceuticals conference call
hosted by Dr. Polymeropoulos (participant passcode 93125446). A
replay of the call will be available Monday, August 10, 2009, at
1:00 PM ET and will be accessible until Monday, August 17, 2009, at
5:00 PM ET. The replay call-in number is 1-888-286-8010 for
domestic callers and 1-617-801-6888 for international callers. The
access number is 78449791. The conference call will be broadcast
simultaneously on the company's Web site,
http://www.vandapharma.com/. Investors should click on the Investor
Relations tab and are advised to go to the Web site at least 15
minutes early to register, download, and install any necessary
software. The call will also be archived on the Vanda Web site for
a period of 30 days, through September 9, 2009. ABOUT VANDA
PHARMACEUTICALS INC.: Vanda Pharmaceuticals Inc. is a
biopharmaceutical company focused on the development and
commercialization of clinical-stage products for central nervous
system disorders. For more on Vanda Pharmaceuticals Inc., please
visit http://www.vandapharma.com/. CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS Various statements in this release are
"forward-looking statements" under the securities laws. Words such
as, but not limited to, "believe," "expect," "anticipate,"
"estimate," "intend," "plan," "targets," "likely," "will," "would,"
and "could," and similar expressions or words, identify
forward-looking statements. Forward-looking statements are based
upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Vanda Pharmaceuticals
Inc. is at an early stage of development and may not ever have any
products that generate significant revenue. Important factors that
could cause actual results to differ materially from those
reflected in the company's forward-looking statements include,
among others: delays in the completion of Vanda's clinical trials;
a failure of Vanda's products to be demonstrably safe and
effective; Vanda's failure to obtain regulatory approval for its
products or to comply with ongoing regulatory requirements for its
products; a lack of acceptance of Vanda's products in the
marketplace, or a failure to become or remain profitable; Vanda's
expectations regarding trends with respect to its costs and
expenses; Vanda's inability to obtain the capital necessary to fund
its commercial and research and development activities; Vanda's
failure to identify or obtain rights to new products; Vanda's
failure to develop or obtain sales, marketing and distribution
resources and expertise or to otherwise manage its growth; a loss
of any of Vanda's key scientists or management personnel; losses
incurred from product liability claims made against Vanda; a loss
of rights to develop and commercialize Vanda's products under its
license and sublicense agreements and other factors that are
described in the "Risk Factors" section (Part II, Item 1A) of
Vanda's quarterly report on Form 10-Q for the fiscal quarter ended
March 31, 2009 (File No. 001-34186). In addition to the risks
described above and in Part II, Item 1A of Vanda's quarterly report
on Form 10-Q, other unknown or unpredictable factors also could
affect Vanda's results. There can be no assurance that the actual
results or developments anticipated by Vanda will be realized or,
even if substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Therefore, no assurance can
be given that the outcomes stated in such forward-looking
statements and estimates will be achieved. All written and verbal
forward-looking statements attributable to Vanda or any person
acting on its behalf are expressly qualified in their entirety by
the cautionary statements contained or referred to herein. Vanda
cautions investors not to rely too heavily on the forward-looking
statements Vanda makes or that are made on its behalf. The
information in this release is provided only as of the date of this
release, and Vanda undertakes no obligation, and specifically
declines any obligation, to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise. VANDA PHARMACEUTICALS INC. (A
Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS (Unaudited) Three Months Ended Six Months Ended
------------------ ---------------- June 30, June 30, June 30, June
30, 2009 2008 2009 2008 ---- ---- ---- ---- Revenue $- $- $- $-
---- ---- ---- ---- Operating expenses: Cost of Sales 229,352 -
229,352 - Research and development 7,195,595 5,480,909 9,528,934
16,583,574 General and administrative 4,988,317 8,454,985 9,212,351
17,414,199 --------- --------- --------- ---------- Total operating
expenses 12,413,264 13,935,894 18,970,637 33,997,773 ----------
---------- ---------- ---------- Loss from operations (12,413,264)
(13,935,894) (18,970,637) (33,997,773) Interest income 21,163
441,012 74,549 1,306,762 Net loss $(12,392,101) $(13,494,882)
$(18,896,088) $(32,691,011) ============ ============ ============
============ Basic and diluted net loss per share attributable to
common stockholders $(0.46) $(0.51) $(0.71) $(1.23) ====== ======
====== ====== Shares used in calculation of basic and diluted net
loss per share attributable to common stockholders 26,900,841
26,649,439 26,777,159 26,648,892 ========== ========== ==========
========== VANDA PHARMACEUTICALS INC. (A Development Stage
Enterprise) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June
30, 2009 December 31, 2008 ------------- ----------------- ASSETS
Current assets: Cash and cash equivalents $24,014,203 $39,079,304
Marketable securities 5,008,623 7,378,798 Prepaid expenses,
deposits and other current assets 1,129,194 1,287,400 Inventory
1,272,240 - --------- --------- Total current assets 31,424,260
47,745,502 Property and equipment, net 1,518,442 1,758,111
Restricted cash 430,230 430,230 Intangible asset, net 11,770,648 -
---------- ---------- Total assets $45,143,580 $49,933,843
=========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities: Accounts payable $6,916,901 $512,382 Accrued
expenses 4,415,231 2,898,417 --------- --------- Total current
liabilities 11,332,132 3,410,799 Long-term liabilities: Deferred
rent 504,811 502,770 ------- ------- Total liabilities 11,836,943
3,913,569 ---------- --------- Stockholders' equity: Common stock
27,140 26,653 Additional paid-in capital 277,149,879 270,988,157
Accumulated other comprehensive income (loss) 213 (20,029) Deficit
accumulated during the development stage (243,870,595)
(224,974,507) ------------ ------------ Total stockholders' equity
33,306,637 46,020,274 ---------- ---------- Total liabilities and
----------- ----------- stockholders' equity $45,143,580
$49,933,843 =========== =========== VANDA PHARMACEUTICALS INC. (A
Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS (Unaudited) Six Months Ended ---------------- June 30,
June 30, 2009 2008 ---- ---- Cash flows from operating activities:
Net loss $(18,896,088) $(32,691,011) Adjustments to reconcile net
income to net cash used in operating activities: Depreciation and
amortization 239,669 259,707 Stock-based compensation 5,279,366
9,074,594 Gain on disposal of assets - 211 Amortization of net
discounts on short-term investments 96,599 (195,911) Amortization
of intangible assets 229,352 - Changes in assets and liabilities:
Prepaid expenses and other current assets 158,206 (247,729)
Inventory (1,272,240) - Accounts payable 1,404,519 2,425,921
Accrued expenses 1,516,814 (5,979,353) Other liabilities 2,041
136,734 ----- ------- Net cash used in operating activities
(11,241,762) (27,216,837) ----------- ----------- Cash flows from
investing activities: Acquisition of intangible asset (7,000,000) -
Purchases of property and equipment - (479,581) Purchases of
marketable securities (8,082,729) (2,081,121) Proceeds from sales
of marketable securities 126,547 4,875,076 Maturities of marketable
securities 10,250,000 39,460,000 ---------- ---------- Net cash
provided by (used in) investing activities (4,706,182) 41,774,374
---------- ---------- Cash flows from financing activities:
Proceeds from exercise of stock options and warrants 882,843 -
------- ------- Net cash provided by financing activities 882,843 -
------- ------- Effect of foreign currency translation - 16,745
------- ------ Net change in cash and cash equivalents (15,065,101)
14,574,282 Cash and cash equivalents, beginning of period
39,079,304 41,929,533 ---------- ---------- Cash and cash
equivalents, end of period $24,014,203 $56,503,815 ===========
=========== Supplemental disclosure of non-cash investing
activities Intangible asset acquisition included in accounts
payable $5,000,000 - DATASOURCE: Vanda Pharmaceuticals Inc.
CONTACT: Stephanie R. Irish, Acting Chief Financial Officer of
Vanda Pharmaceuticals Inc., +1-240-599-4500, Web Site:
http://www.vandapharma.com/
Copyright
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024